A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis
A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska; Flores-Vega, Mariangelis; Melendez, Thomas L; Mondragon, Diana
Trial Phone: 321.841.1324 ; 321-841-4717 ; 321-841-717 ; 321.841.6813 ; 3218419454
-
IRB No: W23.253.12
Protocol Abbrev: EFC17504
Principal Investigator: Amy (Amparo) Gutierrez, MD, FAAN
Phase: Drug: Phase III
Age Group: Adult
Secondary Protocol No: EFC17504
Treatment: frexalimab (SAR441344)
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT06141486
-
Objective
To assess the efficacy of frexalimab compared to placebo in delaying disability progression in nrSPMS.
-
Key Eligibility
nonrelapsing secondary progressive multiple sclerosis
